Peter P Michielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1068531/publications.pdf

Version: 2024-02-01

93 papers 3,366 citations

32 h-index 56 g-index

93 all docs 93 docs citations

93 times ranked 4774 citing authors

#	Article	IF	CITATIONS
1	Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cellular Immunology, 2021, 362, 104283.	1.4	9
2	A rare case of hemodialysis-related portosystemic encephalopathy and review of the literature Acta Clinica Belgica, 2020, 75, 296-300.	0.5	1
3	Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. Surgical Oncology, 2020, 33, 231-238.	0.8	25
4	Adoptive Cell Transfer of Regulatory T Cells Exacerbates Hepatic Steatosis in High-Fat High-Fructose Diet-Fed Mice. Frontiers in Immunology, 2020, 11, 1711.	2.2	19
5	Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda. Journal of Hepatology, 2020, 73, 1271-1273.	1.8	2
6	Diet Reversal and Immune Modulation Show Key Role for Liver and Adipose Tissue T Cells in Murine Nonalcoholic Steatohepatitis. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 467-490.	2.3	26
7	Stable HEV IgG seroprevalence in Belgium between 2006 and 2014. Journal of Viral Hepatitis, 2020, 27, 1253-1260.	1.0	4
8	Nivolumab and anti-HCV activity, a case report. Acta Clinica Belgica, 2020, 76, 1-5.	0.5	3
9	Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population. Annals of Global Health, 2020, 86, 81.	0.8	12
10	1836-P: Nonalcoholic Steatohepatitis (NASH) Significantly Contribute to ß-Cell Function Impairment Independently of Glucose Tolerance Status. Diabetes, 2020, 69, .	0.3	0
11	THU-399-First Belgian hepatitis E seroprevalence study shows low stable birth-cohort specific seroprevalence until, with recent 2016-2018 increase in single centre estimates. Journal of Hepatology, 2019, 70, e331-e332.	1.8	0
12	Biobanking for Viral Hepatitis Research. Frontiers in Medicine, 2019, 6, 183.	1.2	4
13	Outcome of Liver Transplant Patients With High Urgent Priority: Are We Doing the Right Thing?. Transplantation, 2019, 103, 1181-1190.	0.5	14
14	Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. Laboratory Investigation, 2018, 98, 1263-1275.	1.7	33
15	Ethyl Glucuronide in Hair Is an Accurate Biomarker of Chronic Excessive Alcohol Use in Patients With Alcoholic Cirrhosis. Clinical Gastroenterology and Hepatology, 2018, 16, 454-456.	2.4	14
16	Characteristics of patients with hepatitis B virus and hepatitis C virus dual infection in a Western European country: Comparison with monoinfected patients. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 656-663.	0.7	11
17	Influence of Body Mass Index on Hair Ethyl Glucuronide Concentrations. Alcohol and Alcoholism, 2017, 52, 19-23.	0.9	16
18	Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARÎ \pm -regulated dermatopontin. JCI Insight, 2017, 2, .	2.3	96

#	Article	IF	CITATIONS
19	Passenger Lymphocyte Syndrome (PLS): A Single-center Retrospective Analysis of Minor ABO-incompatible Liver Transplants. Journal of Clinical and Translational Hepatology, 2017, 5, 9-15.	0.7	14
20	Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 8271.	1.4	33
21	Ethyl glucuronide concentrations in hair: a controlled alcohol-dosing study in healthy volunteers. Analytical and Bioanalytical Chemistry, 2016, 408, 2019-2025.	1.9	16
22	Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. Journal of Hepatology, 2016, 65, 543-551.	1.8	67
23	Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice. American Journal of Physiology - Renal Physiology, 2016, 311, G599-G609.	1.6	37
24	Liver Fibrosis Evaluation Using Realâ€time Shear Wave Elastography in Hepatitis C–Monoinfected and Human Immunodeficiency Virus/Hepatitis C–Coinfected Patients. Journal of Ultrasound in Medicine, 2016, 35, 1299-1308.	0.8	18
25	Screening for rare variants in the PNPLA3 gene in obese liver biopsy patients. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 715-721.	0.7	3
26	Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness. Hepatology, 2016, 64, 1809-1810.	3.6	22
27	Ethyl glucuronide in hair of non-excessive alcohol consumers: correlations and gender influence. Forensic Toxicology, 2016, 34, 186-190.	1.4	8
28	Hair ethyl glucuronide and serum carbohydrate deficient transferrin for the assessment of relapse in alcohol-dependent patients. Clinical Biochemistry, 2016, 49, 554-559.	0.8	13
29	Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 333-339.	0.7	7
30	Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. PLoS ONE, 2015, 10, e0143380.	1.1	59
31	CD4+ROR $<$ b $<$ i $>$ î $^3<$ li $<$ lb $>$ t++ and Tregs in a Mouse Model of Diet-Induced Nonalcoholic Steatohepatitis. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	25
32	Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients. Clinical Infectious Diseases, 2015, 60, 997-1006.	2.9	64
33	PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2015, 63, 164-173.	1.8	270
34	Validation of APRI and FIB-4 score in an Antwerp cohort of chronic hepatitis C patients. Acta Gastro-Enterologica Belgica, 2015, 78, 373-80.	0.4	3
35	Diagnostic challenges in alcohol use disorder and alcoholic liver disease. World Journal of Gastroenterology, 2014, 20, 8024.	1.4	12
36	Hair ethyl glucuronide levels as a marker for alcohol use and abuse: A review of the current state of the art. Drug and Alcohol Dependence, 2014, 134, 1-11.	1.6	120

#	Article	IF	CITATIONS
37	Hair ethyl glucuronide as a biomarker of alcohol consumption in alcohol-dependent patients: Role of gender differences. Drug and Alcohol Dependence, 2014, 141, 163-166.	1.6	38
38	Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2014, 59, 121-129.	3.6	141
39	Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: A controversial issue. World Journal of Gastroenterology, 2014, 20, 7325.	1.4	88
40	A gene variant of <i>PNPLA3</i> , but not of <i>APOC3</i> , is associated with histological parameters of NAFLD in an obese population. Obesity, 2013, 21, 2138-2145.	1.5	57
41	Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis. International Journal of Molecular Sciences, 2013, 14, 19867-19890.	1.8	56
42	Coinfection of hepatitis B and hepatitis delta virus in Belgium: A multicenter BASL study. Prospective epidemiology and comparison with HBV monoâ€infection. Journal of Medical Virology, 2013, 85, 1513-1517.	2.5	23
43	Hepatitis B virus and hepatitis C virus infections in Belgium. European Journal of Gastroenterology and Hepatology, 2013, 25, 613-619.	0.8	11
44	Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Laboratory Investigation, 2012, 92, 1428-1439.	1.7	100
45	Epidemiology and treatment of autoimmune hepatitis. Hepatic Medicine: Evidence and Research, 2012, 4, 1.	0.9	19
46	Resource use and cost of hepatitis C-related care. European Journal of Gastroenterology and Hepatology, 2012, 24, 1191-1198.	0.8	19
47	Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients. Clinical Gastroenterology and Hepatology, 2012, 10, 1162-1168.	2.4	65
48	The influence of laboratoryâ€induced MELD score differences on liver allocation: more reality than myth. Clinical Transplantation, 2012, 26, E62-70.	0.8	14
49	Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. International Journal of Obesity, 2011, 35, 270-278.	1.6	45
50	Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation i>in vitro i>in vitro i>in vivo i>in	1.9	44
51	Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon- $\hat{l}\pm$ in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3. Gastroenterology, 2010, 139, 1267-1276.e4.	0.6	77
52	Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. European Journal of Gastroenterology and Hepatology, 2010, 22, 1.	0.8	51
53	Clinical trial: a randomized trial of pegylatedâ€interferonâ€Î±â€2a plus ribavirin with or without amantadine in treatmentâ€naìve or relapsing chronic hepatitis C patients. Alimentary Pharmacology and Therapeutics, 2009, 30, 352-363.	1.9	10
54	Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transplantation, 2008, 14, 526-533.	1.3	42

#	Article	IF	Citations
55	Intestinal bowel perforation and bacterial peritonitis secondary to migrated biliary and pancreatic stents. Endoscopy, 2008, 40, E25-E25.	1.0	7
56	Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology, 2007, 46, 388-394.	3.6	107
57	Early prediction of major depression in chronic hepatitis C patients during peg-interferon $\hat{l}\pm -2b$ treatment by assessment of vegetative-depressive symptoms after four weeks. World Journal of Gastroenterology, 2007, 13, 5736.	1.4	20
58	Fine needle trucut biopsy in focal liver lesions: a reliable and safe method in identifying the malignant nature of liver lesions. Acta Gastro-Enterologica Belgica, 2007, 70, 1-5.	0.4	0
59	Oral fluid as a medium for the detection of hepatitis B surface antigen. Journal of Medical Virology, 2005, 77, 53-56.	2.5	30
60	Viral hepatitis and hepatocellular carcinoma. World Journal of Surgical Oncology, 2005, 3, 27.	0.8	125
61	Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. Aids, 2004, 18, 131.	1.0	3
62	Bacillus Calmette???Gu??rin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma. European Journal of Gastroenterology and Hepatology, 2004, 16, 1027-1032.	0.8	30
63	Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. BMC Gastroenterology, 2003, 3, 24.	0.8	16
64	Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial *. Journal of Viral Hepatitis, 2003, 10, 460-466.	1.0	16
65	Elevated serum iron indices in haptoglobin phenotype 2-2 individuals being homozygous for the HFE missense mutation. Journal of Hepatology, 2002, 36, 161.	1.8	0
66	Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. Journal of Hepatology, 2001, 35, 707-711.	1.8	66
67	Diagnosis at first glance: nodular hepatic lesions in persons with AIDS. Clinical Microbiology and Infection, 2001, 7, 576-577.	2.8	0
68	Autoimmune hepatitis, autoimmune gastritis, and gastric carcinoid in a type 1 diabetic patient. Journal of Diabetes and Its Complications, 2000, 14, 116 - 120 .	1.2	23
69	Daily induction treatment with alfa2b interferon in naive chronic hepatitis c patients results in a higher early response, a controlled multicenter randomized trial. Gastroenterology, 2000, 118, A1496-A1497.	0.6	0
70	Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment. Hepatology, 1999, 30, 238-243.	3.6	131
71	Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Gastroenterology, 1999, 117, 408-413.	0.6	146
72	HLA association of amoxicillin-clavulanate–induced hepatitis. Gastroenterology, 1999, 117, 1181-1186.	0.6	267

#	Article	IF	Citations
73	Tolerance and antiviral effects of high-dose interferon-alpha B/D in patients with chronic hepatitis B. Digestive Diseases and Sciences, 1998, 43, 1719-1724.	1.1	O
74	HBV-specific lymphoproliferative and cytokine responses in patients with chronic hepatitis B. Journal of Hepatology, 1998, 28, 8-16.	1.8	47
75	Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. Journal of Hepatology, 1998, 28, 951-959.	1.8	41
76	Hepatitis C virus genotypes: epidemiological and clinical associations. Liver, 1998, 18, 32-38.	0.1	34
77	Thrombolysis in Central Splanchnic Thrombosis. Journal of Intensive Care Medicine, 1997, 12, 269-275.	1.3	O
78	Aminoguanidine reverses aortic hyporeactivity to noradrenaline in portal vein-ligated rats. European Journal of Pharmacology, 1997, 329, 137-146.	1.7	4
79	Fine needle trucut biopsy of focal liver lesions: a new technique. Digestive Diseases and Sciences, 1997, 42, 2077-2081.	1.1	3
80	HLA association of amoxycillin-clavulanate-induced hepatitis: Implications for the pathogenesis of drug-induced immunoallergic hepatitis. Human Immunology, 1996, 47, 160.	1.2	0
81	Acetylcholine-induced vasorelaxation in portal hypertensive rats. Hepatology, 1995, 22, 1009-1011.	3.6	2
82	Role of nitric oxide in hyporeactivity to noradrenaline of isolated aortic rings in portal hypertensive rats. European Journal of Pharmacology, 1995, 273, 167-174.	1.7	27
83	Transjugular intrahepatic portosystemic shunt improves liver function in veno-occlusive disease. Journal of Hepatology, 1994, 21, 685-686.	1.8	9
84	Drug-Induced Gallbladder Disease. Drug Safety, 1992, 7, 32-45.	1.4	36
85	Value of transrectal ultrasonography in Crohn's disease. Gastroenterology, 1991, 101, 1171-1177.	0.6	88
86	A rare cause of colitisâ€" Brucella melitensis. Diseases of the Colon and Rectum, 1991, 34, 194-196.	0.7	18
87	Hepatoportal sclerosis demonstrated by abdominal ultrasonography. Journal of Clinical Ultrasound, 1991, 19, 513-515.	0.4	2
88	Cisapride in Ogilvie's syndrome. Gastroenterology, 1990, 99, 1194.	0.6	8
89	Efficacy of interferon alfa-2b with or without prednisone withdrawal in the treatment of chronic viral hepatitis B. A prospective double-blind Belgian-Dutch study. Journal of Hepatology, 1990, 11, S108-S112.	1.8	40
90	Amoxycillin/clavulanic acid induced cholestasis. Journal of Hepatology, 1990, 11, 392.	1.8	12

PETER P MICHIELSEN

#	Article	IF	CITATIONS
91	Postendoscopic Sphincterotomy Stenosis. Endoscopy, 1989, 21, 237-239.	1.0	3
92	Hematomas after percutaneous liver biopsy. Gastroenterology, 1988, 94, 249.	0.6	3
93	Cardiac Involvement in Juvenile Ceroid Lipofuscinosis of the Spielmeyer-Vogt-Sjögren Type: Prospective Noninvasive Findings in Two Siblings. European Neurology, 1984, 23, 166-172.	0.6	22